NO20032277D0 - Aminotiazoler og deres anvendelse som adenosinreseptorantagonister - Google Patents

Aminotiazoler og deres anvendelse som adenosinreseptorantagonister

Info

Publication number: NO20032277D0
Authority: NO; Norway
Prior art keywords: aminothiazoles; receptor antagonists; adenosine receptor; adenosine; antagonists
Prior art date: 2000-11-21

Application number

NO20032277A

Other languages

English (en)

Other versions

NO20032277L (no

Inventor

Neil John Press

Roger John Taylor

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-21

Filing date

2003-05-20

Publication date

2003-05-20

2003-05-20 Application filed by Novartis Ag filed Critical Novartis Ag

2003-05-20 Publication of NO20032277D0 publication Critical patent/NO20032277D0/no

2003-07-21 Publication of NO20032277L publication Critical patent/NO20032277L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)

NO20032277A 2000-11-21 2003-05-20 Aminotiazoler og deres anvendelse som adenosinreseptorantagonister NO20032277L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0028383.8A GB0028383D0 (en)	2000-11-21	2000-11-21	Organic compounds
PCT/EP2001/013378 WO2002042298A1 (en)	2000-11-21	2001-11-19	Aminothiazoles and their use as adenosine receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20032277D0 true NO20032277D0 (no)	2003-05-20
NO20032277L NO20032277L (no)	2003-07-21

Family

ID=9903594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032277A NO20032277L (no)	2000-11-21	2003-05-20	Aminotiazoler og deres anvendelse som adenosinreseptorantagonister

Country Status (26)

Country	Link
US (1)	US7109202B2 (no)
EP (1)	EP1339711B1 (no)
JP (1)	JP3973556B2 (no)
KR (1)	KR20040007412A (no)
CN (1)	CN1244580C (no)
AR (1)	AR035371A1 (no)
AT (1)	ATE300536T1 (no)
AU (1)	AU2002237221A1 (no)
BR (1)	BR0115478A (no)
CA (1)	CA2429442A1 (no)
CZ (1)	CZ20031393A3 (no)
DE (1)	DE60112322T2 (no)
EC (1)	ECSP034611A (no)
ES (1)	ES2246346T3 (no)
GB (1)	GB0028383D0 (no)
HU (1)	HUP0302079A2 (no)
IL (1)	IL155712A0 (no)
MX (1)	MXPA03004439A (no)
NO (1)	NO20032277L (no)
NZ (1)	NZ525875A (no)
PE (1)	PE20020580A1 (no)
PL (1)	PL361842A1 (no)
RU (1)	RU2003117476A (no)
SK (1)	SK6032003A3 (no)
WO (1)	WO2002042298A1 (no)
ZA (1)	ZA200303721B (no)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020115635A1 (en) *	2001-02-21	2002-08-22	Pnina Fishman	Modulation of GSK-3beta activity and its different uses
EP1452530A4 (en) *	2001-12-03	2005-11-30	Japan Tobacco Inc	AZOL CONNECTION AND THEIR MEDICAL USE
DK1466912T3 (da) *	2002-01-18	2013-07-01	Astellas Pharma Inc	2-acylaminothiazolderivat eller salt deraf
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
TW200524887A (en) *	2003-10-27	2005-08-01	Lundbeck & Co As H	N-thiazol-2-yl-benzamide derivatives
AU2004309279B2 (en) *	2003-12-26	2010-07-15	Kyowa Kirin Co., Ltd.	Thiazole derivative
GB0401336D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
PE20060272A1 (es) *	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0417910D0 (en) *	2004-08-11	2004-09-15	Novartis Ag	Organic compounds
EA200700707A1 (ru) *	2004-09-22	2007-08-31	Х. Лундбекк А/С	Производные 2-ациламинотиазола
SG155924A1 (en) *	2004-09-22	2009-10-29	Lundbeck & Co As H	2-acylaminothiazole derivatives
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
US7674912B2 (en)	2005-04-25	2010-03-09	H. Lundbeck A/S	Pro-drugs of N-thiazol-2-yl-benzamide derivatives
CN101247807A (zh) *	2005-05-09	2008-08-20	艾其林医药公司	噻唑化合物及使用方法
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
JP2008543754A (ja) *	2005-06-09	2008-12-04	メルクエンドカムパニーインコーポレーテッド	チェックポイントキナーゼの阻害剤
US20100280023A1 (en) *	2005-06-23	2010-11-04	Kyowa Hakko Kogyo Co., Ltd.	Thiazole derivatives
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
HUE034666T2 (hu) *	2005-08-02	2018-02-28	Kyowa Hakko Kirin Co Ltd	Szer alvászavar kezelésére és/vagy megelõzésére
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
US7994211B2 (en)	2005-08-08	2011-08-09	Argenta Discovery Limited	Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP5341516B2 (ja) *	2005-09-13	2013-11-13	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	２−アニリン−４−アリール置換チアゾール誘導体
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
US20070203153A1 (en) *	2005-11-08	2007-08-30	Astellas Pharma Inc.	Compositions and methods for treating thrombocytopenia
GB0526244D0 (en)	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
RU2457842C2 (ru) *	2006-03-17	2012-08-10	Гайлид Пало Альто, Инк.	Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
WO2007118149A2 (en) *	2006-04-07	2007-10-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege	Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
JP2010500361A (ja) *	2006-08-08	2010-01-07	アカークス，インコーポレーテッド	ヒトの血小板レベルを増加させるための組成物および方法
MX2009003185A (es)	2006-09-29	2009-04-03	Novartis Ag	Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en)	2006-10-30	2008-05-08	Novartis Ag	Heterocyclic compounds as antiinflammatory agents
HRP20110201T1 (hr)	2007-01-10	2011-08-31	Irm Llc	Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
DE602008005140D1 (de)	2007-05-07	2011-04-07	Novartis Ag	Organische verbindungen
MX2010004177A (es)	2007-10-18	2010-05-03	Janssen Pharmaceutica Nv	1,2,4-triazoles trisustituidos.
JO2784B1 (en)	2007-10-18	2014-03-15	شركة جانسين فارماسوتيكا ان. في	5,3,1 - Triazole substitute derivative
AR069637A1 (es)	2007-12-10	2010-02-10	Novartis Ag	Derivados de pirazinas
CN101970405A (zh)	2007-12-14	2011-02-09	普尔马金医疗(哮喘)有限公司	吲哚及其治疗用途
CN101910153B (zh)	2008-01-11	2014-01-22	诺华股份有限公司	作为激酶抑制剂的嘧啶类
EP2244706B1 (en) *	2008-02-25	2016-04-06	Merck Patent GmbH	Glucokinase activators
ES2442932T3 (es)	2008-03-19	2014-02-14	Janssen Pharmaceutica N.V.	1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
CL2009001125A1 (es)	2008-05-09	2011-02-11	Janssen Pharmaceutica Nv	Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
WO2009150137A2 (en)	2008-06-10	2009-12-17	Novartis Ag	Organic compounds
CN101747327B (zh) *	2008-12-02	2013-03-27	中国人民解放军军事医学科学院毒物药物研究所	芳酰胺基噻唑类衍生物及其制备方法和用途
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
GB0902648D0 (en)	2009-02-17	2009-04-01	Argenta Discovery Ltd	Pharmaceutical compounds and compositions
JP2012517992A (ja)	2009-02-17	2012-08-09	チェシファーマスーティシエス．ピー．エイ．	Ｐ３８ｍａｐキナーゼインヒビターとしてのトリアゾロピリジン誘導体
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
US20110166112A1 (en) *	2009-08-14	2011-07-07	Eisai, Inc.	Method for stimulating platelet production
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt)	2009-08-20	2016-03-01	Novartis Ag	compostos de oxima heterocíclica
JP2013508414A (ja)	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症および他の慢性疾患の治療のための組成物
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201009731D0 (en)	2010-06-10	2010-07-21	Pulmagen Therapeutics Inflamma	Kinase inhibitors
AU2011271510A1 (en)	2010-06-30	2013-01-10	Gilead Sciences, Inc.	Use of A2B adenosine receptor antagonists for treating pulmonary hypertension
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
BR112013021638A2 (pt)	2011-02-25	2016-08-02	Irm Llc	"compostos inibidores de trk, seu uso e composições que os compreendem"
WO2012125400A1 (en) *	2011-03-14	2012-09-20	Acorn Biomedical, Inc.	Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases
AR085942A1 (es)	2011-04-07	2013-11-06	Gilead Sciences Inc	Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en)	2011-09-15	2018-07-18	Novartis AG	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN103946221B (zh)	2011-09-16	2016-08-03	诺华股份有限公司	用于治疗囊性纤维化的杂环化合物
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
DE102011083283A1 (de) *	2011-09-23	2013-03-28	Beiersdorf Ag	Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
BR112014013178A2 (pt)	2011-12-09	2017-06-13	Chiesi Farm Spa	composto, composição farmacêutica e uso de um composto
PT2788349T (pt)	2011-12-09	2017-02-02	Chiesi Farm Spa	Inibidores de cinase
SG10201604656YA (en)	2011-12-09	2016-07-28	Chiesi Farma Spa	Kinase inhibitors
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
JP2015512425A (ja)	2012-04-03	2015-04-27	ノバルティスアーゲー	チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
CN102964343A (zh) *	2012-12-10	2013-03-13	湖南大学	N-酰基-4-叔丁基-5-（1,2,4-三唑-1-基）噻唑-2-胺及其制备方法与应用
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
BR112015029970A2 (pt)	2013-06-06	2017-07-25	Chiesi Farm Spa	inibidores de cinase
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
CN106458979B (zh)	2014-04-24	2020-03-27	诺华股份有限公司	作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
EP3134396B1 (en)	2014-04-24	2019-09-18	Novartis AG	Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016023967A2 (pt)	2014-04-24	2017-08-15	Novartis Ag	derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
CN105367564B (zh) *	2014-09-01	2018-03-23	湖南大学	N‑[4‑苯基‑5‑(1，2，4‑三唑‑1‑基)噻唑‑2‑基]酰胺及其制备与应用
TW201720828A (zh)	2015-11-23	2017-06-16	赫孚孟拉羅股份公司	治療性化合物及組合物以及其使用方法
SG11201805237TA (en)	2015-12-21	2018-07-30	Council Scient Ind Res	Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereof
EP3394059B1 (en)	2015-12-23	2020-11-25	Chiesi Farmaceutici S.p.A.	1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
EP3394058B1 (en)	2015-12-23	2020-10-14	Chiesi Farmaceutici S.p.A.	N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3394060A1 (en)	2015-12-23	2018-10-31	Chiesi Farmaceutici S.p.A.	1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
EP3452464B1 (en)	2016-05-05	2021-12-15	F. Hoffmann-La Roche AG	Pyrazole derivatives, compositions and therapeutic use thereof
KR20190045302A (ko)	2016-09-06	2019-05-02	에프. 호프만-라 로슈 아게	8-(아제티딘-1-일)-[1,2,4]트라이아졸로[1,5-a]피리딘일 화합물 및 이의 조성물 및 사용 방법
BR112019013287A2 (pt)	2016-12-29	2019-12-24	Hoffmann La Roche	compostos de pirazolopirimidina e métodos de uso dos mesmos
ES2676535B1 (es) *	2017-01-20	2019-04-29	Palobiofarma Sl	Moduladores de los receptores a3 de adenosina
WO2018166993A2 (en)	2017-03-14	2018-09-20	F. Hoffmann-La Roche Ag	Pyrazolochlorophenyl compounds, compositions and methods of use thereof
US20180334465A1 (en)	2017-05-22	2018-11-22	Genentech, Inc.	Therapeutic compounds and compositions, and methods of use thereof
CR20190520A (es)	2017-05-22	2020-01-21	Hoffmann La Roche	Composiciones y compuestos terapéuticos y métodos para utilizarlos
US10364245B2 (en)	2017-06-07	2019-07-30	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
CN109293652B (zh) *	2017-07-24	2021-10-22	四川科伦博泰生物医药股份有限公司	一种取代的噻唑衍生物及其用途
KR102007640B1 (ko)	2017-11-29	2019-08-07	퓨쳐메디신 주식회사	아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
WO2019139714A1 (en)	2018-01-15	2019-07-18	Genentech, Inc.	Pyrazolopyrimidine compounds as jak inhibitors
AU2020290094B2 (en)	2019-06-10	2024-01-18	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
WO2020257142A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
PH12021552998A1 (en)	2019-06-18	2023-08-14	Hoffmann La Roche	Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
PE20220346A1 (es)	2019-08-28	2022-03-14	Novartis Ag	Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2023139132A1 (en) *	2022-01-19	2023-07-27	Leadxpro Ag	Functionalized aminothiazoles
GB2615307A (en) *	2022-01-28	2023-08-09	Adorx Therapeutics Ltd	Antagonist compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8917849D0 (en) *	1989-08-04	1989-09-20	Shell Int Research	Thiazole derivatives,their preparation and their use as fungicides
JPH04118648A (ja)	1990-07-13	1992-04-20	Konica Corp	写真用カプラー
FR2677356B1 (fr) *	1991-06-05	1995-03-17	Sanofi Sa	Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
JPH07128824A (ja)	1993-11-05	1995-05-19	Konica Corp	写真用カプラー
US5530000A (en) *	1993-12-22	1996-06-25	Ortho Pharmaceutical Corporation	Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
AU3201095A (en) *	1994-07-27	1996-02-22	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
US5880140A (en) *	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) *	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6080870A (en)	1996-04-03	2000-06-27	Merck & Co., Inc.	Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5854265A (en) *	1996-04-03	1998-12-29	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en) *	1996-04-03	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5859035A (en) *	1996-04-03	1999-01-12	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
US5874452A (en) *	1996-04-03	1999-02-23	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US6063930A (en)	1996-04-03	2000-05-16	Merck & Co., Inc.	Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5872136A (en) *	1996-04-03	1999-02-16	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
EP0914322A1 (en)	1996-05-27	1999-05-12	Fujisawa Pharmaceutical Co., Ltd.	New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
ATE257703T1 (de)	1997-10-27	2004-01-15	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
AU4506399A (en)	1998-06-05	1999-12-30	Novartis Ag	Aryl pyridinyl thiazoles
AU2164300A (en)	1998-12-04	2000-06-26	N.V. Organon	Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
JP2000302680A (ja)	1999-04-23	2000-10-31	Takeda Chem Ind Ltd	脳保護剤
WO2000066124A1 (fr)	1999-04-28	2000-11-09	Sankyo Company, Limited	Agents preventifs ou inhibiteurs destines a une hepatopathie
AU2001239754A1 (en)	2000-02-25	2001-09-03	Avon Products Inc.	Topical compositions containing thiazolium compounds and methods of using same
WO2001064674A1 (en)	2000-03-01	2001-09-07	Janssen Pharmaceutica N.V.	2,4-disubstituted thiazolyl derivatives

2000
- 2000-11-21 GB GBGB0028383.8A patent/GB0028383D0/en not_active Ceased
2001
- 2001-11-19 IL IL15571201A patent/IL155712A0/xx unknown
- 2001-11-19 MX MXPA03004439A patent/MXPA03004439A/es unknown
- 2001-11-19 CZ CZ20031393A patent/CZ20031393A3/cs unknown
- 2001-11-19 EP EP01986395A patent/EP1339711B1/en not_active Expired - Lifetime
- 2001-11-19 US US10/432,302 patent/US7109202B2/en not_active Expired - Fee Related
- 2001-11-19 BR BR0115478-8A patent/BR0115478A/pt not_active Application Discontinuation
- 2001-11-19 NZ NZ525875A patent/NZ525875A/en unknown
- 2001-11-19 ES ES01986395T patent/ES2246346T3/es not_active Expired - Lifetime
- 2001-11-19 HU HU0302079A patent/HUP0302079A2/hu unknown
- 2001-11-19 AR ARP010105397A patent/AR035371A1/es unknown
- 2001-11-19 RU RU2003117476/04A patent/RU2003117476A/ru not_active Application Discontinuation
- 2001-11-19 PL PL01361842A patent/PL361842A1/xx not_active Application Discontinuation
- 2001-11-19 CN CNB018192882A patent/CN1244580C/zh not_active Expired - Fee Related
- 2001-11-19 SK SK603-2003A patent/SK6032003A3/sk unknown
- 2001-11-19 CA CA002429442A patent/CA2429442A1/en not_active Abandoned
- 2001-11-19 KR KR10-2003-7006156A patent/KR20040007412A/ko not_active Ceased
- 2001-11-19 AT AT01986395T patent/ATE300536T1/de not_active IP Right Cessation
- 2001-11-19 AU AU2002237221A patent/AU2002237221A1/en not_active Abandoned
- 2001-11-19 DE DE60112322T patent/DE60112322T2/de not_active Expired - Lifetime
- 2001-11-19 WO PCT/EP2001/013378 patent/WO2002042298A1/en not_active Ceased
- 2001-11-19 JP JP2002544432A patent/JP3973556B2/ja not_active Expired - Fee Related
- 2001-11-20 PE PE2001001159A patent/PE20020580A1/es not_active Application Discontinuation
2003
- 2003-05-14 ZA ZA200303721A patent/ZA200303721B/en unknown
- 2003-05-16 EC EC2003004611A patent/ECSP034611A/es unknown
- 2003-05-20 NO NO20032277A patent/NO20032277L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2002042298A1 (en)	2002-05-30
JP3973556B2 (ja)	2007-09-12
DE60112322D1 (de)	2005-09-01
CN1476447A (zh)	2004-02-18
NZ525875A (en)	2004-11-26
ES2246346T3 (es)	2006-02-16
AR035371A1 (es)	2004-05-12
PL361842A1 (en)	2004-10-04
CA2429442A1 (en)	2002-05-30
KR20040007412A (ko)	2004-01-24
HUP0302079A2 (hu)	2003-09-29
SK6032003A3 (en)	2004-01-08
CN1244580C (zh)	2006-03-08
ATE300536T1 (de)	2005-08-15
MXPA03004439A (es)	2003-08-19
US7109202B2 (en)	2006-09-19
US20040053982A1 (en)	2004-03-18
GB0028383D0 (en)	2001-01-03
ECSP034611A (es)	2003-06-25
AU2002237221A1 (en)	2002-06-03
NO20032277L (no)	2003-07-21
EP1339711A1 (en)	2003-09-03
DE60112322T2 (de)	2006-05-24
EP1339711B1 (en)	2005-07-27
BR0115478A (pt)	2004-02-17
JP2004521871A (ja)	2004-07-22
ZA200303721B (en)	2004-05-10
CZ20031393A3 (cs)	2003-08-13
PE20020580A1 (es)	2002-08-13
RU2003117476A (ru)	2005-02-10
IL155712A0 (en)	2003-11-23

Publication	Publication Date	Title
NO20032277L (no)	2003-07-21	Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO20031952L (no)	2003-07-22	3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
ATE317844T1 (de)	2006-03-15	Adenosine a2a receptor antagonisten
NO20034324L (no)	2003-09-26	Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DE60110219D1 (de)	2005-05-25	Adenosin a2a rezeptor antagonisten
DK1498413T3 (da)	2011-12-05	4-aminopicolinater og deres anvendelse som herbicider
DK1455785T3 (da)	2009-06-08	Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
ATE293962T1 (de)	2005-05-15	Adenosin-rezeptor modulatoren
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20040469L (no)	2004-04-30	Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20025357L (no)	2002-11-08	Antranylamider og deres anvendelse som legemidler
DK1478629T3 (da)	2007-01-29	N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DE60234951D1 (de)	2010-02-11	Adenosin a2a rezeptor antagonisten
NO20025150L (no)	2002-12-16	2-acylindolderivater og deres anvendelse som antitumormidler
NO20025640L (no)	2003-01-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
DK1581518T3 (da)	2011-06-06	Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
DK1335906T3 (da)	2007-02-05	Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20040499L (no)	2004-03-31	Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
NO20034434D0 (no)	2003-10-03	Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
NO20043799L (no)	2004-09-10	2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
NO20035486D0 (no)	2003-12-10	Benzodiazepinderivater og deres anvendelse som AMPA- reseptorstimulatorer
NO20022455D0 (no)	2002-05-24	Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander
NO20000324D0 (no)	2000-01-21	Benzotia (oksa) diazolderivater og deres anvendelse som endotelinreseptorantagonister

Legal Events

Date	Code	Title	Description
2006-07-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application